Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02847728 · ClinicalTrials.gov registry record

Pattern of Use and Safety/Effectiveness of Nivolumab in Routine Oncology Practice

A clinical trial of Lung Cancer and Melanoma, sponsored by Bristol-Myers Squibb.

Completed
Registry status
1,189
Enrollment target
20
Study locations

NCT02847728 is a study of Lung Cancer and Melanoma that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 1,189 participants, above the 933-participant average among 409 other Lung Cancer trials with a reported enrollment target (27% higher). The trial reports 20 study locations across 14 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02847728, a study of Lung Cancer and Melanoma, has completed, sponsored by Bristol-Myers Squibb.

COMPLETED
Registry status
1,189 participants
Enrollment target
20
Study locations

Study Summary

This is an observational, multicenter study in participants treated with nivolumab for the approved indications of melanoma and Lung cancer in Australia, the EU, Switzerland, the United Kingdom (UK), and the United States (US). The targeted countries in the EU for study participation include Austria, Belgium, Czech Republic, France, Germany, Hungary, Italy, Poland, and Spain. Study objectives are to assess the safety experience, survival, adverse event management, and outcomes of adverse events associated with nivolumab in routine oncology care facilities.

Conditions Studied

Lung Cancer Melanoma

Study Locations (20)

Other

  • Local Institution - 1103 - Innsbruck
  • Local Institution - 1102 - Klagenfurt
  • Local Institution - 1101 - Krems

Florida

  • Local Institution - 1912 - Jacksonville
  • Local Institution - 1907 - Lake City

Texas

  • Local Institution - 1915 - El Paso
  • Local Institution - 1905 - Fort Sam Houston

New South Wales

  • Local Institution - 1001 - Lismore
  • Local Institution - 1002 - Wagga Wagga

Victoria

  • Local Institution - 1006 - Franskton
  • Local Institution - 1003 - Wodonga

California

  • Local Institution - 1909 - Palm Springs

Illinois

  • Local Institution - 1901 - Park Ridge

Louisiana

  • Local Institution - 1910 - Alexandria

Trial Details

FieldValue
Enrollment Target 1,189 participants
Start Date 2016-07-28
Est. Completion 2024-03-31

Sponsor

Bristol-Myers Squibb

1,025 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02847728

The ClinicalTrials.gov registry entry for NCT02847728 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1,189 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 933-participant average among 409 other Lung Cancer trials with a reported enrollment target (27% higher). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Lung Cancer appearing as the primary indexed condition, and to 0 interventions.

NCT02847728 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Other, Florida, Texas.

Frequently Asked Questions

What is clinical trial NCT02847728 about?

NCT02847728 is a clinical study titled "Pattern of Use and Safety/Effectiveness of Nivolumab in Routine Oncology Practice". This is an observational, multicenter study in participants treated with nivolumab for the approved indications of melanoma and Lung cancer in Australia, the EU, Switzerland, the United Kingdom (UK), and the United States (US). The targeted countries in the EU for study participation include Austria...

What is the current status of trial NCT02847728?

This trial is currently completed. The enrollment target is 1,189 participants. The study started on 2016-07-28. Estimated completion is 2024-03-31.

What conditions does trial NCT02847728 study?

This clinical trial studies the following conditions: Lung Cancer, Melanoma.

Who is sponsoring clinical trial NCT02847728?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02847728 being conducted?

This trial has 20 study locations across California, Florida, Illinois, Louisiana, Mississippi. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Lung Cancer

All registered trials for this condition

Melanoma

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.